Leyden Labs

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Leyden Labs headquartered in Europe, operates in the Biotechnology, Life Science, Therapeutics sector. The company focuses on Biotechnology and has secured $4.5B in funding across 24 round(s). With a team of 51-100 employees, Leyden Labs is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Leyden Labs, raised $140.0M. Discover more about their projects, partnerships, and impact on our platform.